Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis [HEL cell lines]
PubMed Full text in PMC Similar studies Analyze with GEO2R
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis [MPN patients]
Physical interaction between mutant calreticulin and the thrombopoietin receptor is required for transformation of hematopoietic cells
PubMed Full text in PMC Similar studies SRA Run Selector
JAK2 Naive and Persitent Murine BaF3 cells infected with MPLW515L
Targeting the CALR Interactome in Myeloproliferative Neoplasms
Expression data from C. elegans harboring type 1-like and type 2-like calreticulin mutations of MPN patients
CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response
PubMed Similar studies
RNA-seq of Myeloproliferative neoplasms primary CD34+ HSPCs and cell lines after tamoxifen treatment
PubMed Full text in PMC Similar studies
RNAseq of JAK2V617F-positive MPN cell lines after 4-Hydroxytamoxifen treatment
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Bulk RNAseq of primary CD34+ HSPCs in Myeloproliferative neoplasms patients receiving tamoxifen
CALR frameshift mutations accelerate maturation of megakaryocytes in MPN patient-derived iPS cells
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression (RNA-Seq)
Pbx1 expression is required for myeloproliferative neoplasm onset and maintenance
Metabolic Alterations in JAK2 Mutant Hematopoietic Cells Represent Therapeutic Vulnerabilities for Myeloproliferative Neoplasms
Mapping STAT1 pS727 occupancy and effect of cortistatin A (CA) on STAT1 occupancy in JAK2-driven neoplasms
Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms
Quantitative Analysis of Erythroblast Transcriptomes in Control and NUP-17d Treatment Groups
The JAK2-STAT pathway epigenetically regulates tolerized genes during the first encounter to bacterial antigens
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on